Research

Hormonal

Current clinical evidence from randomized controlled trials and meta-analyses does not support a causal link between GLP-1 receptor agonist use and an increased risk of thyroid cancer in humans.

If you are considering or taking a GLP-1 medication (like Ozempic or Wegovy) and are worried about thyroid cancer, know that large human studies have not found a proven link. The warning on the label comes from animal studies, not human outcomes. While you should be aware of symptoms, the proven benefits for weight loss and heart health generally outweigh this unproven risk. Do not stop your medication without talking to your doctor, especially if you have a family history of specific thyroid cancers (MTC), which is a separate contraindication.

GoodRefutesHIGH confidence
Evidence from randomized controlled trials indicates occurrence of thyroid cancer is infrequent in individuals exposed to GLP-1 RA. ... Overall there is no conclusive evidence of elevated thyroid cancer risk.
Ana E. Espinosa De Ycaza et al. · Thyroid · 2024

Why this rating

The review prioritizes RCTs and meta-analyses as the strongest evidence for causality, noting they show infrequent occurrence.

Source

Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review

Ana E. Espinosa De Ycaza et al. · Thyroid · 2024

DOI 10.1089/thy.2023.0530

narrative_reviewCited 29×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →